New Perioperative Strategy in Gastric Cancer

The new perioperative strategy in gastric cancer involves incorporating immunotherapy into the existing chemotherapy regimen to improve outcomes for patients with resectable gastric and gastroesophageal junction cancers. These cancers are highly aggressive, with high recurrence rates even after surgery and chemotherapy. The current standard treatment, known as the FLOT regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel), has shown survival benefits but remains insufficient to address the high recurrence rates.

To address this gap, the phase 3 MATTERHORN clinical trial investigated the addition of durvalumab, an immune checkpoint inhibitor targeting PD-L1 (programmed death-ligand 1), to the FLOT regimen. Durvalumab is designed to enhance the immune system's ability to recognize and attack cancer cells.

Early results from the MATTERHORN trial have been promising, showing higher response rates and a potential survival benefit when durvalumab is added to the FLOT chemotherapy regimen. This suggests that immunotherapy, when combined with standard perioperative chemotherapy, could significantly improve outcomes for patients with resectable gastric and gastroesophageal junction cancers.

In summary, the new perioperative strategy highlights the potential of integrating immunotherapy (durvalumab) with FLOT chemotherapy to reduce recurrence rates and improve survival in patients with these challenging cancers. This approach represents a significant advancement in the treatment landscape for gastric cancer.